Skip to main content

Table 4 Adverse events

From: Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer

 

Trifluridine/tipiracil plus bevacizumab group (N = 60)

Trifluridine/tipiracil monotherapy group (N = 66)

Any grade (%)

Grade 3 (%)

Grade 4 (%)

Any grade (%)

Grade 3 (%)

Grade 4 (%)

Hematological

 Neutropenia

41 (68.3)

25 (41.7)

5 (8.3)

47 (71.2)

19 (28.8)

8 (12.1)

 Leucopenia

49 (81.7)

23 (38.3)

0 (0)

47 (71.2)

17 (25.8)

2 (3.0)

 Anemia

52 (86.7)

8 (13.3)

1 (1.7)

60 (90.9)

12 (18.2)

2 (3.0)

 Thrombocytopenia

26 (43.3)

1 (1.7)

1 (1.7)

24 (36.4)

2 (3.0)

0 (0)

Non-hematological

 Proteinuria

25 (41.7)

4 (6.7)

0 (0)

9 (13.6)

1 (1.5)

0 (0)

 Hypertension

23 (38.3)

4 (6.7)

0 (0)

11 (16.7)

0 (0)

0 (0)

 Febrile neutropenia

2 (3.3)

2 (3.3)

0 (0)

5 (7.8)

5 (7.8)

0 (0)

 Gastrointestinal perforation

2 (3.3)

2 (2.9)

0 (0)

1 (1.5)

1 (1.5)

0 (0)

 Fatigue

30 (50.0)

0 (0)

0 (0)

25 (37.9)

0 (0)

0 (0)

 Anorexia

25 (41.7)

0 (0)

0 (0)

27 (40.9)

1 (1.5)

0 (0)

 Nausea

10 (16.7)

0 (0)

0 (0)

15 (22.7)

0 (0)

0 (0)

 Diarrhea

5 (8.3)

0 (0)

0 (0)

8 (12.1)

0 (0)

0 (0)

 Vomiting

2 (3.3)

0 (0)

0 (0)

4 (6.1)

0 (0)

0 (0)